eFFECTOR Therapeutics Inc (NASDAQ: EFTR) announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer. In the ZFA triplet cohort, patients received 0.07 mg/kg zotatifin combined with fulvestrant and abemaciclib. The median progression-free survival was 7.4 months. As previously reported, 5/19 (26%) RECIST-evaluable patients had partial responses, including four confirmed and one unconfirmed. The ZFA triplet was generally well tolerated, with most zotatifin-related treat…